RELIEF, a strategic project for GlioCure, selected by EUREKA!
Angers, France - GlioCure SAS, a biotechnology company specialized in neuro-oncology, announces that the RELIEF project, in which it is a partner alongside the German SME Abnoba and the Universities of Angers (France), Utrecht (Netherlands) and Uppsala (Sweden), has been selected by the intergovernmental association for the promotion of innovation EUREKA! through its twelfth Eurostars call for projects.
The RELIEF project aims to develop a drug delivery system (functionalized asymmetric liposomes) to better target and treat brain tumours after intravenous injections. The first indication targeted is glioblastoma (GBM) - the most frequent and aggressive brain tumour - with the GC01 peptide developed by GlioCure as the active pharmaceutical ingredient.
RELIEF represents a 3-year global R&D effort of approximately €2.8M for the five partners, including €630,000 for GlioCure which will provide the GC01 peptide and assume responsibility for tasks related to in vitro and in vivo anti-GBM activity proof-of-concept .
As such, GlioCure could receive up to €252,000 in grants from Bpifrance over the next three years, representing 40% of its R&D effort on the project.
"The RELIEF project is strategic for GlioCure as it broadens our pharmaceutical and galenic development options for our first anti-tumor molecule" according to Louis-Marie Bachelot, President and co-founder of GlioCure. He also underlines that "the selection of this project under the Eurostars scheme is a new demonstration, after the selection of the Gliogel project by EuroNanomed III in 2017, of GlioCure's ability to be part of collaborative R&D excellence projects at the European level".
The RELIEF project has been labellised by the Atlanpole Biothérapies competitiveness cluster of which GlioCure and the University of Angers are members.
About GlioCure :
GlioCure is a spin-off of the Universities of Angers and McGill Montreal specialized in neuro-oncology.
Positioned in the field of diseases affecting glial cells, cells that are essential to the proper functioning of neurons and the brain, GlioCure is dedicated to identifying, selecting and developing new molecules of interest, particularly for the treatment of brain tumors.
GlioCure has thus initiated the development of a first active ingredient, GC01, in the treatment of glioblastoma, the most frequent and aggressive brain tumor.
More information is available on our website: www.gliocure.com.
Media and Investor Relations Contacts :
Louis-Marie Bachelot, Chairman, +33(0)6 14 03 38 26, lm.bachelot@gliocure.com